Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2017 07:01 ET | Source: Cellect Biotechnology Ltd.

Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.

TEL AVIV, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cell isolation technology, announced today that the U.S. Food & Drug...
April 03, 2017 06:02 ET | Source: Cellect Biotechnology Ltd.

Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications

Patent to provide coverage in both U.S. and EU Method of treatment patent provides protection in diabetes, inflammatory bowel disease, graft-versus-host disease and transplant rejection TEL AVIV,...
March 27, 2017 07:02 ET | Source: Cellect Biotechnology Ltd.

Cellect Announces Successful First Cancer Patient Stem Cell Transplant

Cellect’s technology, ApoGraft™, aims to become a game changer in stem cells transplantations for cancer treatments Company gets green light from DSMB Board for enrolling additional 2 cancer...
March 23, 2017 07:05 ET | Source: Cellect Biotechnology Ltd.

Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results

TEL AVIV, Israel, March 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells,...
March 02, 2017 07:01 ET | Source: Cellect Biotechnology Ltd.

Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors

TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, today announced the appointment of Dr....
February 23, 2017 11:00 ET | Source: Cellect Biotechnology Ltd.

Cellect to Ring the NASDAQ Stock Market Opening Bell on Friday, February 24th

TEL AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, announced today that the Company will ring...
February 23, 2017 07:00 ET | Source: Cellect Biotechnology Ltd.

World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board

TEL AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, announced today that Dr. Corey Cutler,...
February 21, 2017 07:01 ET | Source: Cellect Biotechnology Ltd.

Cellect Announces Positive Clinical Trial Results

ApoGraft TM, Cellect’s flagship technology, validated as safe, robust and reproducible process for clinical use after a 104 donor test base Cellect CEO: “In plain words, these positive results bring...
February 14, 2017 16:01 ET | Source: Cellect Biotechnology Ltd.

Dual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange

TEL AVIV, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, announced today that it will file a petition...
February 08, 2017 07:05 ET | Source: Cellect Biotechnology Ltd.

First Cancer Patient Treated In Phase I/II Trial of ApoGraft™

Management expects additional positive upcoming results from its trial in healthy volunteers TEL AVIV, Israel, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd....